The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC),…
Despite significant improvements in the perception of biomarker testing compared to a 2018 survey, substantial barriers to implementation persist globally,…